October 27, 12:00 PM – 1:30 PM ET
Overview
Technological innovations in molecular testing via tissue or liquid biopsy have enabled clinicians to expand beyond the identification of common mutations in lung cancer genes like EGFR to include rarer actional mutations, such as MET amplifications and HER2 genetic alterations. Although each of these mutations may individually drive only 1% to 5% of tumors, they collectively account for many patients with non–small cell lung cancer (NSCLC).
This virtual symposium brings together a panel of experts in the diagnosis and management of NSCLC to provide case-based illustrations on how to apply emerging molecular testing technologies to the treatment of NSCLC.
Benefits of Attending
- Access expert insights on guideline-recommended strategies to apply molecular testing results to the treatment of patients with NSCLC
- Stay up-to-date on emerging biomarkers and therapies for the treatment of NSCLC
- Bring the latest information on testing technology in NSCLC to your clinical practice
Target Audience
This educational activity is directed toward medical oncologists, pathologists, NP/PAs, and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Determine the importance of multidisciplinary management for the assessment and interpretation of molecular data in advanced NSCLC
- Explain current biomarkers and mutational tests, including NGS and liquid biopsy tests, that support personalization of therapy in advanced NSCLC
- Apply efficacy and safety data from trials that evaluated current and emerging therapies in the context of clinical guidelines for management of advanced NSCLC
- Describe emerging therapeutic targets and assessment strategies in advanced NSCLC
Thursday, October 27, 2022 |
||
12:00 PM |
Welcome and Introductions |
Charu Aggarwal, MD, MPH |
12:05 PM |
The Role of Biopsy and Testing Technology in NSCLC: Current Options |
Lynette M. Sholl, MD |
12:15 PM |
Applying Test Results to Treatment Plans: Current and Emerging Markers in Therapies |
David R. Gandara, MD |
12:25 PM |
From Results to Treatment Plans: Case-Based Illustrations on Applying Testing Results to Treatment |
Moderator: Charu Aggarwal, MD, MPH |
1:20 PM |
Q&A Session |
Moderator: Charu Aggarwal, MD, MPH |
1:30 PM |
Adjourn |
|
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
Associate Director, Clinical Penn Center for Precision Medicine
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA
Disclosures: Grant/Research Support: My Institution: AstraZeneca/Medlummune, Genentech/ Roche, lncyte, MacroGenics, Merck Sharp & Dohme; Consultant: AstraZeneca, BeiGene, Blueprint Genetics, Boehringer lngelheim, Celgene, Daiichi Sankyo/AstraZeneca, Eisai, Eli Lilly and Co., Genentech, Janssen, Merck, Pfizer, Regeneron/Sanofi, Shionogi, and Turning Point Therapeutics.
David R. Gandara, MD
Professor of Medicine Emeritus
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Adjunct Clinical Professor, Translational and Clinical Research Program, University of Hawaii Cancer Center
Chief Medical Officer, International Society of Liquid Biopsy
Sacramento, CA
Disclosures: Grant/Research Support: Amgen, AstraZeneca, Genentech, Merck; Consultant: Adagene (Institutional), AstraZeneca (Institutional), Biotech (Institutional), Guardant Health (Institutional), IO Oncocyte (Institutional), OncoHost (Institutional), Roche-Genentech (Institutional).
Lynette M. Sholl, MD
Associate Professor, Pathology
Harvard Medical School
Associate Pathologist, Pathology
Brigham And Women’s Hospital
Boston, MA
Disclosures: Grant/Research Support: Genentech, Bristol Myers Sqibb, Lilly; Consultant: Astra Zeneca, GV20 Therapeutics.
Ignacio I. Wistuba, MD
Professor and Chair, Department of Translational Molecular Pathology
Division of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Genentech, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, Akoya; Consultant: Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Flame, Novartis, Sanofi, Daiichi Sankyo, Jansen, Regeneron, Amgen, Oncocyte, MSD; Speakers’ Bureau: Medscape, MSD, Genentech/Roche, Platform Health, Pfizer, AstraZeneca, Merck.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.